Went back to the 2001 annual report- about 21 million shares outstanding at that time- in 2005 the annual report showed about 51 million outstanding. didn't they just recently dilute again- By the time they get a product to market there will be even more shares outstanding- Theyu just don't have the $$$$ to develop drugs on their own. just opinion
Market Data 
Markets 
AI
